Melorheostosis and its treatment with intravenous zoledronic acid
- PMID: 22479293
- PMCID: PMC3047172
- DOI: 10.1136/bcr.04.2009.1757
Melorheostosis and its treatment with intravenous zoledronic acid
Abstract
We report a case of melorheostosis, a rare bone disorder characterised by mesodermal dysplasia, and its successful and prolonged treatment with the intravenous bisphosphonate zoledronic acid. The middle-aged man presented with pain and swelling of his tibia, which was diagnosed by imaging and bone biopsy as being due to melorheostosis. There was early symptom control after a single infusion of intravenous zoledronic acid. Prolonged symptom relief was accompanied by long-term suppression of the bone resorption marker β cross-laps. We suggest that melorheostosis can be treated with intravenous zoledronic acid and that treatment can be monitored by the use of a specific bone resorption marker.
Figures
References
-
- Freyschmidt J: Melorheostosis: a review of 23 cases. Eur Radiol 2001; 11: 474–9 - PubMed
-
- Brown RR, Steiner G, Lehman WB: Melorheostosis: case report with radiologic-pathologic correlation. Skeletal Radiol 2000; 29: 548–52 - PubMed
-
- Morris JM, Samilson RL, Corley CL. Melorheostosis. Review of the literature and report of an interesting case with nineteen year follow up. J Bone Joint Surg 1963; 45A: 1191–2000 - PubMed
-
- Judkiewicz AM, Murphey MD, Resnik CS, et al. Advanced imaging of melorheostosis with emphasis on MRI. Skeletal Radiol 2001; 30: 447–53 - PubMed
-
- Baer SC, Ayala AG, Ro JY, et al. Case report 843. Malignant fibrous histiocytoma of the femur arising in melorheostosis. Skeletal Radiol 1994; 23: 310. - PubMed
LinkOut - more resources
Full Text Sources